Bright Minds Biosciences announces receipt of NASDAQ Notification Letter Regarding Minimum Bid Price Deficiency
Vancouver, British Columbia, January 27, 2023 – Bright Minds Biosciences Inc. (CSE:DRUG) (NASDAQ:DRUG) (“Bright Minds” or the “Company”) announces that it has received a notification letter (the “Notification Letter”) from the Nasdaq Stock Market LLC (“NASDAQ”) dated January 26, 2023, notifying the Company that due to thirty consecutive business days of closing bid prices for…
